KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Assets: 2010-2025

Historic Assets for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $1.5 billion.

  • Emergent BioSolutions' Assets fell 1.14% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 1.14%. This contributed to the annual value of $1.4 billion for FY2024, which is 23.78% down from last year.
  • Emergent BioSolutions' Assets amounted to $1.5 billion in Q3 2025, which was up 3.10% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Assets registered a high of $3.2 billion during Q4 2022, and its lowest value of $1.4 billion during Q4 2024.
  • Its 3-year average for Assets is $1.8 billion, with a median of $1.5 billion in 2024.
  • In the last 5 years, Emergent BioSolutions' Assets climbed by 27.27% in 2021 and then slumped by 42.42% in 2023.
  • Quarterly analysis of 5 years shows Emergent BioSolutions' Assets stood at $3.0 billion in 2021, then increased by 7.05% to $3.2 billion in 2022, then plummeted by 42.42% to $1.8 billion in 2023, then dropped by 23.78% to $1.4 billion in 2024, then fell by 1.14% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.4 billion during Q1 2025.